

A Stereoselective Three-Component Reaction: The Facile Synthesis of Fluorinated Tetrahydropyrimido[1,2-b]benzothiazoles

A. Shaabani*, A. Rahmati, A.H. Rezayan and H.R. Khavasi
Department of Chemistry, Shahid Beheshti University, P.O. Box 19396-4716 Tehran, Iran

(Received 2 October 2008, Accepted 10 December 2009)

A one-pot, catalyst- and solvent-free approach has been developed for the stereoselective synthesis of fluorinated tetrahydropyrimido[1,2-b]benzothiazoles. The three-component condensation reaction of an aldehyde and a trifluoromethyl β -dicarbonyl compound in the presence of 2-aminobenzothiazole occurs in high yields at 90 °C.

Keywords: Fluorinated compound, 2-Aminobenzothiazole, 3-Amino-1,2,4-triazole, Solvent-free, Catalyst-free

INTRODUCTION

Recently, the synthesis of organofluorine compounds has received significant attention due to their biological activities [1-5]. Among these, heterocyclic compounds containing trifluoromethyl group are attractive targets for medicinal chemistry [6-8]. Some of the most well-known drugs are Prozac (anti-depressant), Diflucan (anti-fungal agent), Casodex (anti-cancer agent) and Desflurane (inhalation anesthetic) [9]. Mosher's acid and its derivatives are another important class of CF_3 -containing compounds, which are widely used as chiral NMR resolution agents [10-12]. Therefore, the exploration of new effective methods for their synthesis is axiomatic.

Due to the atom economy, convergent character and simplicity of one-pot procedures, multi-component condensation reactions (MCRs) occupy a superior position compared with other reactions. Therefore, the discovery and development of novel MCRs is attracting growing interest from industrial chemistry research groups [13]. One of the first substrate classes involved in MCRs was the 1,3-dicarbonyl

derivatives, which they used for the selective construction of highly functionalized small organic molecules with high synthetic and biological value [14,15]. However, a careful literature search reveals that the reaction of 2-aminobenzothiazole and aldehydes with ethyl 4,4,4-trifluoroacetoacetate under MCR strategy has not been studied.


In pursuit of our ongoing studies in the synthesis of new fluorinated organic compounds [16-18] and our growing interest in MCRs, Biginelli and Biginelli-like reactions [19-24], herein we wish to report the stereoselective synthesis of fluorinated tetrahydropyrimido[1,2-b]benzothiazoles ring systems *via* the one-pot three-component condensation reaction of an aldehyde **1** and ethyl 4,4,4-trifluoroacetoacetate **2** in the presence of 2-aminobenzothiazole **3** under solvent-free conditions at 90 °C without using any catalyst (Scheme 1).

EXPERIMENTAL

Apparatus

Melting points were measured on an Electrothermal 9100 apparatus. Mass spectra were recorded on a FINNIGAN-MAT 8430 mass spectrometer operating at an ionization potential of 70 eV. IR spectra were recorded on a Shimadzu IR-470

*Corresponding authors. E-mail: a-shaabani@cc.sbu.ac.ir



Scheme 1

spectrometer. ^1H and ^{13}C NMR spectra were recorded on a BRUKER DRX-300.13 AVANCE spectrometer at 300.13.13 and 75.47 MHz, respectively. NMR spectra were obtained on solutions in CDCl_3 and $\text{DMSO-}d_6$.

Typical Procedure for the Synthesis of Ethyl-4-(trifluoromethyl)-4-hydroxy-6-(4-methylphenyl)-1,4,5,6-tetrahydropyrimido[1,2-b]benzothiazole-3-carboxylate (4a, $\text{C}_{21}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_3\text{S}$)

A mixture of ethyl 4,4,4-trifluoroacetate (0.184 g, 1 mmol), *para*-methylbenzaldehyde (0.120 g, 1 mmol), and 2-aminobenzthiazole (0.150 g, 1 mmol) was successively added to a screw-capped vial containing a magnetic stirring bar and was heated at 90 °C in a preheated oil bath for 2 h. After completion of the reaction, the solid residue was crystallized from $\text{CH}_2\text{Cl}_2/n$ -hexane 1:1 to yield 0.357 g of **4a** as a white powder (82%). m.p.: 161-163 °C. IR (KBr, cm^{-1}): 3155, 1736, 1584, 1562, 1506. ^1H NMR (300 MHz, CDCl_3): δ 1.01 (t, $J = 7.1$ Hz, 3H, OCH_2CH_3), 2.36 (s, 3H, $\text{C}_6\text{H}_4\text{CH}_3$), 3.06 (d, $J = 11.4$ Hz, 1H, CHCOOEt), 3.97-4.08 (m, 2H, OCH_2CH_3), 4.64 (brs, 1H, OH), 5.36 (d, $J = 11.4$ Hz, 1H, CH-N), 6.14-7.30 (m, 8CH arom) ppm. ^{13}C NMR (75 MHz, CDCl_3): δ 13.63 (OCH_2CH_3), 21.13 ($\text{C}_6\text{H}_4\text{CH}_3$), 49.90 (CHCOOEt), 57.69 (CH-N), 61.91 (OCH_2CH_3), 82.21 (q, $^2J_{\text{CF}} = 31.1$ Hz, C-OH), 113.39 (C arom), 121.87 (C arom), 122.62 (C arom), 122.79 (C arom), 123.80 (q, $^1J_{\text{CF}} = 286.5$ Hz, CF_3), 125.42 (C arom), 127.24 (C arom), 130.03 (C arom), 132.52 (C arom), 138.36 (C arom), 139.25 (C arom), 164.99 (C=N), 170.86 (C=O) ppm. ^{19}F NMR (282 MHz, CDCl_3): δ -82 (s, 3F, CF_3) ppm. MS (EI, 70 eV): m/z (%) = 436 (M^+ , 2), 286 (5), 217 (38), 150 (100), 69 (60). Anal. Calcd. for $\text{C}_{21}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_3\text{S}$: C, 57.79; H, 4.39; N, 6.42; S, 7.35. Found: C, 56.92; H, 4.01; N, 6.27; S, 7.43.

Ethyl-4-(trifluoromethyl)-4-hydroxy-6-(phenyl)-1,4,5,6-tetrahydropyrimido[1,2-b]benzothiazole-3-carboxylate

(**4b**, $\text{C}_{20}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_3\text{S}$). White powder (0.354 g, 84%): m.p.: 139-140 °C. IR (KBr, cm^{-1}): 3070, 1739, 1584, 1561, 1462. ^1H NMR (300 MHz, CDCl_3): δ 0.99 (t, $J = 7.1$ Hz, 3H, OCH_2CH_3), 3.05 (d, $J = 11.4$ Hz, 1H, CHCOOEt), 3.97-4.05 (m, 2H, OCH_2CH_3), 4.70 (brs, 1H, OH), 5.44 (d, $J = 11.4$ Hz, 1H, CH-N), 6.12-7.30 (m, 8CH arom). ^{13}C NMR (75 MHz, CDCl_3): δ 13.65 (OCH_2CH_3), 49.99 (CHCOOEt), 57.99 (CH-N), 61.96 (OCH_2CH_3), 82.10 (q, $^2J_{\text{CF}} = 31.0$ Hz, C-OH), 113.46 (C arom), 121.98 (C arom), 122.68 (C arom), 123.06 (C arom), 124.50 (q, $^1J_{\text{CF}} = 283.5$ Hz, CF_3), 125.54 (C arom), 127.42 (C arom), 129.38 (C arom), 129.41 (C arom), 135.54 (C arom), 138.16 (C arom), 165.16 (C=N), 170.42 (C=O). MS (EI, 70 eV): m/z (%) = 422 (M^+ , 18), 353 (80), 272 (15), 246 (35), 177 (100), 150 (85), 69 (70). Anal. Calcd. for $\text{C}_{20}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_3\text{S}$: C, 56.87; H, 4.06; N, 6.63; S, 7.59. Found: C, 56.48; H, 3.95; N, 6.72; S, 7.44.

Ethyl-4-(trifluoromethyl)-4-hydroxy-6-(4-methoxyphenyl)-1,4,5,6-tetrahydropyrimido[1,2-b]benzothiazole-3-carboxylate (4c, $\text{C}_{21}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_4\text{S}$)

White powder (0.342 g, 78%): m.p.: 146-148 °C. IR (KBr, cm^{-1}): 3120, 1737, 1586, 1565, 1506. ^1H NMR (300 MHz, CDCl_3): δ 1.04 (t, $J = 7.1$ Hz, 3H, OCH_2CH_3), 3.12 (d, $J = 11.4$ Hz, 1H, CHCOOEt), 3.82 (s, 3H, $\text{C}_6\text{H}_4\text{OCH}_3$), 3.99-4.08 (m, 2H, OCH_2CH_3), 4.60 (brs, 1H, OH), 5.46 (d, $J = 11.4$ Hz, 1H, CH-N), 6.23-7.37 (m, 8CH arom). ^{13}C NMR (75 MHz, CDCl_3): δ 13.70 (OCH_2CH_3), 50.00 (CHCOOEt), 55.35 (CH-N), 57.59 ($\text{C}_6\text{H}_4\text{OCH}_3$), 62.00 (OCH_2CH_3), 81.93 (q, $^2J_{\text{CF}} = 32.1$ Hz, C-OH), 113.69 (C arom), 114.75 (C arom), 121.99 (C arom), 122.70 (C arom), 123.04 (C arom), 123.60 (q, $^1J_{\text{CF}} = 280.3$ Hz, CF_3), 125.66 (C arom), 127.10 (C arom), 128.70 (C arom), 138.29 (C arom), 160.19 (C arom), 165.20 (C=N), 170.57 (C=O). MS (EI, 70

eV): m/z (%) = 452 (M^+ , 2), 302 (5), 257 (30), 233 (50), 150 (50), 69 (100). Anal. Calcd. for $C_{21}H_{19}F_3N_2O_4S$: C, 55.75; H, 4.23; N, 6.19; S, 7.09. Found: C, 56.16; H, 4.12; N, 5.97; S, 7.34.

Ethyl-4-(Trifluoromethyl)-4-hydroxy-6-(4-bromophenyl)-1,4,5,6-tetrahydropyrimido[1,2-b]benzo-thiazole-3-carboxylate (4d, $C_{20}H_{16}BrF_3N_2O_3S$). White powder (0.405 g, 81%): m.p.: 142-144 °C. IR (KBr, cm^{-1}): 3230, 1732, 1592, 1580, 1483. 1H NMR (300 MHz, $CDCl_3$): δ 1.06 (t, $J = 7.1$ Hz, 3H, OCH_2CH_3), 3.00 (d, $J = 11.3$ Hz, 1H, $CHCOOEt$), 3.99-4.05 (m, 2H, OCH_2CH_3), 4.60 (brs, 1H, OH), 5.42 (d, $J = 11.3$ Hz, 1H, $CH-N$), 6.09-7.52 (m, 8CH arom). ^{13}C NMR (75 MHz, $CDCl_3$): δ 13.75 (OCH_2CH_3), 49.86 ($CHCOOEt$), 57.19 ($CH-N$), 62.04 (OCH_2CH_3), 82.23 (q, $^2J_{CF} = 31.1$ Hz, $C-OH$), 113.11 (C arom), 121.74 (C arom), 122.53 (C arom), 123.09 (C arom), 123.30 (C arom), 125.58 (C arom), 129.05 (C arom), 130.16 (q, $^1J_{CF} = 289.00$ Hz, CF_3), 132.59 (C arom), 134.93 (C arom), 137.94 (C arom), 164.86 ($C=N$), 169.99 ($C=O$). MS (EI, 70 eV): m/z (%) = 501 (M^+ , 2), 433 (^{81}Br , 10), 431 (^{79}Br , 8), 352 (^{81}Br , 4), 350 (^{79}Br , 6), 307 (^{81}Br , 18), 305 (^{79}Br , 20), 283 (^{81}Br , 23), 281 (^{79}Br , 25), 150 (100), 69 (40). Anal. Calcd. for $C_{20}H_{16}BrF_3N_2O_3S$: C, 47.92; H, 3.22; N, 5.59; S, 6.40. Found: C, 47.63; H, 3.41; N, 5.66; S, 6.27.

Ethyl-4-(trifluoromethyl)-4-hydroxy-6-(4-chlorophenyl)-1,4,5,6-tetrahydropyrimido[1,2-b]benzothiazole-3-carboxylate (4e, $C_{20}H_{16}ClF_3N_2O_3S$). White powder (0.426 g, 93%): m.p.: 138-139 °C. IR (KBr, cm^{-1}): 3200, 1734, 1597, 1575, 1486. 1H NMR (300 MHz, $CDCl_3$): δ 1.05 (t, $J = 6.96$ Hz, 3H, OCH_2CH_3), 3.01 (d, $J = 11.3$ Hz, 1H, $CHCOOEt$), 3.96-4.07 (m, 2H, OCH_2CH_3), 4.75 (brs, 1H, OH), 5.42 (d, $J = 11.3$ Hz, 1H, $CH-N$), 6.05-7.43 (m, 8CH arom). ^{13}C NMR (75 MHz, $CDCl_3$): δ 13.70 (OCH_2CH_3), 49.86 ($CHCOOEt$), 57.14 ($CH-N$), 62.07 (OCH_2CH_3), 82.20 (q, $^2J_{CF} = 31.2$ Hz, $C-OH$), 113.12 (C arom), 122.05 (C arom), 122.57 (C arom), 123.08 (C arom), 124.15 (q, $^1J_{CF} = 290.5$ Hz, CF_3), 125.57 (C arom), 128.77 (C arom), 129.65 (C arom), 134.35 (C arom), 135.20 (C arom), 137.95 (C arom), 164.88 ($C=N$), 170.14 ($C=O$). MS (EI, 70 eV): m/z (%) = 458 (M^+ , 4), 389 (6), 306 (15), 150 (100), 69 (35). Anal. Calcd. for $C_{20}H_{16}ClF_3N_2O_3S$: C, 52.58; H, 3.53; N, 6.13; S, 7.02. Found: C, 53.22; H, 3.75; N, 5.98; S, 7.24.

Ethyl-4-(trifluoromethyl)-4-hydroxy-6-(4-nitrophenyl)-1,4,5,6-tetrahydropyrimido[1,2-b]benzothiazole-3-carbo-

xylate (4f, $C_{20}H_{16}F_3N_3O_3S$). Pale yellow powder (0.364 g, 78%): m.p.: 156-158 °C. IR (KBr, cm^{-1}): 3105, 1737, 1585, 1570, 1518. 1H NMR (300 MHz, $DMSO-d_6$): δ 1.07 (t, $J = 6.8$ Hz, 3H, OCH_2CH_3), 3.04 (d, $J = 10.7$ Hz, 1H, $CHCOOEt$), 4.02-4.11 (m, 2H, OCH_2CH_3), 5.59 (d, $J = 10.7$ Hz, 1H, $CH-N$), 6.02-8.26 (m, 8CH arom). ^{13}C NMR (75 MHz, $DMSO-d_6$): δ 14.02 (OCH_2CH_3), 46.13 ($CHCOOEt$), 55.42 ($CH-N$), 61.41 (OCH_2CH_3), 82.99 (q, $^2J_{CF} = 33.2$ Hz, $C-OH$), 110.66 (C arom), 123.83 (C arom), 124.38 (C arom), 127.83 (q, $^1J_{CF} = 285.7$ Hz, CF_3), 128.20 (CH arom), 138.37 (C arom), 139.53 (C arom), 144.35 (C arom), 146.56 (C arom), 147.06 (C arom), 148.01 (C arom), 162.56 ($C=N$), 168.84 ($C=O$). MS (EI, 70 eV): m/z (%) = 449 ($M^+ - H_2O$, 2), 400 (5), 350 (10), 325 (20), 282 (100), 236 (60), 150 (70), 108 (68), 69 (55). Anal. Calcd. for $C_{20}H_{16}F_3N_3O_3S$: C, 51.39; H, 3.45; N, 8.99; S, 6.86. Found: C, 50.89; H, 3.36; N, 9.14; S, 6.52.

Ethyl-4-(trifluoromethyl)-4-hydroxy-6-(3-nitrophenyl)-1,4,5,6-tetrahydropyrimido[1,2-b]benzothiazole-3-carboxylate (4g, $C_{20}H_{16}F_3N_3O_3S$). Pale yellow powder (0.420 g, 90%): m.p.: 175-177 °C. IR (KBr, cm^{-1}): 3095, 1729, 1590, 1524, 1567. 1H NMR (300 MHz, $DMSO-d_6$): δ 1.13 (t, $J = 6.9$ Hz, 3H, OCH_2CH_3), 3.37 (d, $J = 10.7$ Hz, 1H, $CHCOOEt$), 4.03-4.09 (m, 2H, OCH_2CH_3), 6.02 (d, $J = 10.7$ Hz, 1H, $CH-N$), 6.60-8.18 (m, 8CH arom). ^{13}C NMR (75 MHz, $DMSO-d_6$): δ 14.00 (OCH_2CH_3), 46.20 ($CHCOOEt$), 55.23 ($CH-N$), 61.40 (OCH_2CH_3), 83.31 (q, $^2J_{CF} = 30.2$ Hz, $C-OH$), 110.60 (C arom), 121.82 (C arom), 121.96 (C arom), 122.79 (C arom), 123.17 (C arom), 123.63 (C arom), 124.31 (q, $^1J_{CF} = 280.3$ Hz, CF_3), 127.04 (C arom), 130.15 (C arom), 133.74 (C arom), 139.48 (C arom), 141.20 (C arom), 148.20 (C arom), 162.76 ($C=N$), 168.94 ($C=O$). MS (EI, 70 eV): m/z (%) = 468 (MH^+ , 8), 398 (25), 248 (80), 150 (95), 69 (100). Anal. Calcd. for $C_{20}H_{16}F_3N_3O_3S$: C, 51.39; H, 3.45; N, 8.99; S, 6.86. Found: C, 51.70; H, 3.56; N, 8.73; S, 6.54.

6-(Trifluoromethyl)-pyrimido[1,2-b]benzothiazole-4-one (6, $C_{11}H_6F_3N_3O$). White powder (0.215 g, 85%): m.p.: >280 °C. IR (KBr, cm^{-1}): 3140, 1680, 1606, 1585, 1486. 1H NMR (300 MHz, $DMSO-d_6$): δ 6.45 (s, 1H, CH), 7.37-8.45 (m, 4CH arom). ^{13}C NMR (75 MHz, $DMSO-d_6$): δ 99.39 (CH), 111.88 (C arom), 116.34 (C arom), 121.71 (q, $^1J_{CF} = 274.1$ Hz, CF_3), 122.86 (C arom), 125.96 (C arom), 127.28 (C arom), 130.86 (C arom), 150.37 (C arom), 151.31 (q, $^2J_{CF} = 33.8$ Hz, $C-CF_3$), 159.42 ($C=O$). MS (EI, 70 eV): m/z (%) = 253 (M^+ , 100), 225

(70) 206 (15), 184 (25), 156 (25), 133 (35), 90 (25), 69 (40).
 Anal. Calcd. for C₁₁H₆F₃N₃O: C, 52.18; H, 2.39; N, 16.60.
 Found: C, 51.94; H, 2.51; N, 17.02.

RESULT AND DISCUSSION

The reaction of an aldehyde with ethyl 4,4,4-trifluoroacetoacetate in the presence of 2-aminobenzothiazole led to stereoselective formation of fluorinated tetrahydropyrimido[1,2-b]benzothiazoles **4a-g** in relatively high yields. The structures of the products were deduced from their IR, ¹H NMR and ¹³C NMR spectra. The mass spectra of these compounds displayed molecular ion peaks at the appropriate *m/z* values. The ¹H NMR spectra of **4a** consisted of a triplet for the CH₃CH₂O group ($\delta = 1.01$), a singlet for the CH₃C₆H₄ ($\delta = 2.36$), a doublet of doublet for the two CH groups ($\delta = 3.06$ and 5.36 ppm, ³*J*_{HH} = 11.4 Hz), and a multiplet for CH₃CH₂O ($\delta = 3.94$ - 4.08). A broad signal for the OH group appeared at $\delta = 4.64$ and a multiple for the aromatic hydrogen's appeared at $\delta = 6.14$ - 7.30 . The ¹H decoupled ¹³C NMR spectrum of **4a** showed 19 distinct resonances (two quartet at 82.21 (²*J*_{CF} = 31.12 Hz) for C-OH and 123.80 (¹*J*_{CF} = 286.50 Hz) for CF₃ and also 17 signal for other carbons) in agreement with the suggested structure. The ¹H and ¹³C NMR spectra of **4b-g** were similar to those of **4a** except for the R¹ group, which exhibited characteristic signals with appropriate chemical shifts.

To explore the scope and limitations of this reaction

further, we extended our studies to the use of various *meta* and *para*-substituted benzaldehydes in the presence of 2-aminobenzothiazole. As indicated in Table 1, the reaction proceeded efficiently with both electron-withdrawing and electron-releasing *meta* and *para*-substituted benzaldehydes.

It is important to note that 2-aminobenzimidazole **5** react with fluorinate β -dicarbonyl compound (under the identical conditions) in a different manner, yielding 6-(trifluoromethyl)-pyrimido[1,2-b]benzothiazole-4-one **6** (Scheme 2). Formation of the latter evidently proceeds without the participation of the aldehyde component and is competitive with the three-component condensation reaction. Probably, this is a result of the higher nucleophilicity of the -NH₂ group of 2-aminobenzimidazole as compared to 2-aminobenzothiazol. The high nucleophilicity of NH₂ group in 2-aminobenzimidazole in comparison to 2-aminobenzothiazol may be explained by the higher aromaticity of imidazole ring relative to thiazol ring. In other words, NH₂ group in 2-aminobenzimidazole is less conjugated with imidazole ring relative to thiazol ring.


Compound **4a** has three stereogenic centers, and therefore four diastereomers are expected (Scheme 3). The ¹H NMR spectra of the crude reaction mixture obtained from **4a-g** showed a doublet of doublet at $\delta = 3.00$ - 3.12 ppm and $\delta = 5.36$ - 5.59 ppm (³*J*_{HH} = 10.66 to 11.44 Hz) for the H-5 and H-6 protons, respectively. These data were consistent with the presence of an anti-HCCH arrangement diastereomers (4R,5R,6S or 4S,5R,6S and their mirror image geometries).

Crystal structure determination [25,26] of **4a** (Fig. 1)


Table 1. Synthesis of Fluorinated Tetrahydropyrimido[1,2-b]benzothiazoles

Entry	R ¹	Product	Time (min)	Yield (%)
1	4-Me	4a	120	82
2	H	4b	60	84
3	4-OMe	4c	100	78
4	4-Cl	4d	60	81
5	4-Br	4e	45	93
6	4-NO ₂	4f	35	78
7	3-NO ₂	4g	15	90

A Stereoselective Three-Component Reaction



Scheme 2



Scheme 3





Fig. 1. (a): ORTEP representation of **4a**, (b): Side view of the compound that shows the anti configuration of the H5 and H6 hydrogens.



Scheme 4

clearly showed that vicinal OH-4 and COOEt groups are syn, and the **(4R,5S,6R)-4a** and its mirror image **(4S,5R,6S)-4a** is confirmed.

We have not established a mechanism for the formation of tetrahydropyrimido[1,2-b]benzothiazoles systems, but a reasonable possibility is indicated in Scheme 4. The reaction presumably proceeds in three steps: condensation of aldehyde **1** and ethyl 4,4,4-trifluoroacetoacetate **2** by a standard *Knoevenagel* reaction to produce 3-benzylidene-2,4-pentanedione **7**, followed by a *Michael* addition of this product with 2-aminobenzothiazole **3** to give **8** which cyclizes to afford tetrahydropyrimido[1,2-b]benzothiazoles ring systems **4a-g** (Scheme 4).

In conclusion, we have introduced a novel stereoselective three-component condensation reaction leading to fluorinated tetrahydropyrimido[1,2-b]benzothiazoles systems in excellent yields from simple and readily available precursor under neutral conditions without using any catalyst or activator.

ACKNOWLEDGEMENTS

We gratefully acknowledge the financial support from the Research Council of Shahid Beheshti University.

REFERENCES

- [1] J. Fried, E.T. Sabo, *J. Am. Chem. Soc.* 76 (1954) 1455.
- [2] T. Himaya, *Organofluorine Compounds*, Springer-Verlag, Berlin, Heidelberg, 2001.
- [3] B. Tcrck, G.K.S. Prakash, *Adv. Synth. Catal.* 345 (2003) 165.
- [4] K. Uneyama, In *Organofluorine Chemistry*, Blackwell: Oxford, 2006.
- [5] P. Kirsch, *Modern Fluoroorganic Chemistry: Synthesis, Reactivity, Applications*, Wiley-VCH, New York, Heidelberg, 2004.
- [6] W. Pang, S. Zhu, H. Jiang, S. Zhu, *Tetrahedron* 62 (2006) 11760.
- [7] M. Schlosser, *Angew. Chem., Int. Ed.* 45 (2006) 5432.
- [8] S.V. Druzhinin, E.S. Balenkova, V.G. Nenajdenko, *Tetrahedron* 63 (2007) 7753.
- [9] R. Filler, in: P.V. Ramachandran (Ed.), *Asymmetric Fluoroorganic Chemistry*, ACS Symp. Series, ACS, Washington, DC, Chap. 1, 2000, p.1.
- [10] J.A. Dale, H.S. Mosher, *J. Am. Chem. Soc.* 90 (1968) 3732.
- [11] J.A. Dale, H.S. Mosher, *J. Am. Chem. Soc.* 95 (1973) 512.
- [12] P. Yan, B. Tcrck, G.K.S. Prakash, G.A. Olah, *Synlett* 4 (2003) 527.
- [13] J. Zhu, H. Bienagme, *Multi Component Reaction*, Wiley-VCH, 2005.
- [14] F. Lieby-Muller, C. Simon, T. Constantieux, J. Rodriguez, *QSAR Comb. Sci.* 25 (2006) 432.
- [15] C. Simon, T. Constantieux, J. Rodriguez, *Eur. J. Org. Chem.* 2004, 4957.
- [16] A. Shaabani, A. Bazgir, K. Soleimani, H.R. Bijanzadeh, *J. Flourin. Chem.* 116 (2002) 93.
- [17] A. Shaabani, M.B. Teimouri, I. Yavari, H. Norouzi-Arasi, H.R. Bijanzadeh, *J. Flourin. Chem.* 103 (2000) 155.
- [18] I. Yavari, A. Shaabani, S. Asghari, M.M. Olmstead, N. Safari, *J. Flourin. Chem.* 86 (1997) 77.
- [19] A. Shaabani, A. Rahmati, S. Naderi, *Bioorg. Med. Chem. Lett.* 15 (2005) 5553.
- [20] A. Shaabani, E. Farhangi, A. Rahmati, *Com. Chem. High Throughput Screening* 9 (2006) 771.
- [21] A. Shaabani, A. Rahmati, A.H. Rezayan, M. Darvishi,

A Stereoselective Three-Component Reaction

- Z. Badri, A. Sarvari, QCS Com. Science 26 (2007) 973.
- [22] A. Shaabani, A.H. Rezayan, A. Sarvari. H.R. Khavasi, Tetrahedron Lett. 49 (2008) 1469.
- [23] A. Shaabani, A.H. Rezayan, A. Rahmati, A. Sarvari, Synlett (2007) 1458.
- [24] A. Shaabani, E. Soleimani, A.H. Rezayan, A. Sarvari, Org. Lett. 10 (2008) 2581.
- [25] Crystal data analyses: Stoe IPDSII two-circle diffractometer, Mo_{Kα} radiation ($\lambda = 0.71073$); T = 293(2) K; Graphite monochromator; numerical absorption correction. Structure solution by direct methods using SHELXS and refinement by full-matrix least-squares on F² using SHELXL of the X-STEP32 suite of programs¹⁹ all non-hydrogen atoms were refined anisotropically. Crystal data for 5a: C₂₁H₁₉F₃N₂O₃S₁, M = 436.45 g mol⁻¹; crystal dimensions 0.40 × 0.30 × 0.18 mm³; triclinic, space group P $\bar{1}$; a = 9.1301(16), b = 11.0347(18), c = 11.4617(19) Å, $\alpha = 82.405(13)^\circ$, $\beta = 71.517(7)^\circ$, $\gamma = 67.117(12)^\circ$, V = 1008.9(3) Å³; Z = 2; F(000) = 452, $\rho_{\text{calc}} = 1.437$ g cm⁻³; 2.00° < θ < 29.24°; section of the reciprocal lattice: -10 ≤ h ≤ 12, -15 ≤ k ≤ 15, -15 ≤ l ≤ 15; of 10999 measured reflections, 5400 were independent and 5400 with I > 2σ(I); absorption coefficient 0.213 mm⁻¹; R1 = 0.0857 and wR2 = 0.1950 for I > 2σ(I); largest peak (0.473 e Å⁻³) and hole (-0.579 e Å⁻³). (CCDC No.663161).
- [26] Stoe & Cie, X-STEP32, Version 1.07b: Crystallographic package; Stoe & Cie GmbH: Darmstadt, Germany, 2000.